Orchard Laboratories Corp

Orchard Laboratories Corp was paid $25.29M by Medicaid between Jan 2018 and Dec 2024, across 147 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 40% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#8 of 108

Median peer was paid$588K

This provider vs. median43×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	11,657	$1.23M
2019	17,830	$2.14M
2020	67,334	$5.79M
2021	179,987	$9.28M
2022	130,861	$4.97M
2023	73,414	$1.87M
2024incomplete	34,844	$735.20

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	40%	147,361	118,871	$10.17M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	29%	57,642	50,093	$7.46M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	8.5%	24,187	21,387	$2.15M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	7.4%	97,926	86,445	$1.87M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	2.6%	6,455	6,308	$665K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.6%	13,417	6,137	$648K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	2.1%	9,654	7,277	$539K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	1.2%	16,185	13,180	$312K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,551	1,531	$241K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	7,745	5,298	$108K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	4,192	3,748	$92K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	4,659	3,967	$89K

135 more codes

87481		<1%	5,408	$76K
86769		<1%	1,597	$73K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	5,419	$69K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	5,320	$61K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	5,318	$59K
87653		<1%	4,053	$54K
80053	Comprehensive metabolic panel	<1%	8,098	$43K
87640		<1%	2,212	$34K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,985	$30K
84443	Thyroid stimulating hormone (TSH)	<1%	4,392	$30K
85004		<1%	5,680	$25K
80061	Lipid panel	<1%	4,339	$22K
87563		<1%	2,097	$22K
86328		<1%	636	$20K
87529		<1%	702	$20K
87511		<1%	2,101	$19K
87581		<1%	1,290	$18K
83036	Hemoglobin; glycosylated (A1C)	<1%	4,510	$18K
87486		<1%	1,275	$18K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	884	$17K
87631		<1%	553	$15K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,400	$13K
87806		<1%	1,414	$13K
82607		<1%	2,177	$11K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,300	$10K
81514		<1%	325	$9K
86804		<1%	1,462	$8K
86409		<1%	136	$7K
82652		<1%	331	$7K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,603	$6K
86705		<1%	1,066	$5K
85027		<1%	1,641	$5K
86709		<1%	1,082	$5K
82746		<1%	1,123	$5K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	<1%	5,081	$5K
87498		<1%	322	$5K
87186		<1%	1,315	$5K
83735		<1%	1,319	$4K
86696		<1%	584	$4K
87541		<1%	226	$4K
84439		<1%	1,515	$4K
87340		<1%	860	$4K
84134		<1%	337	$3K
80164		<1%	301	$3K
80177		<1%	302	$3K
86695		<1%	587	$3K
81003		<1%	3,111	$3K
83540		<1%	1,070	$2K
87634		<1%	320	$2K
84153		<1%	436	$2K
36415	Collection of venous blood by venipuncture	<1%	8,881	$2K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	188	$2K
80370		<1%	54	$2K
84402		<1%	147	$2K
84480		<1%	316	$2K
80326		<1%	51	$2K
87641		<1%	86	$1K
82728		<1%	357	$1K
83718		<1%	484	$1K
83550		<1%	329	$1K
84460		<1%	566	$1K
84450		<1%	558	$975.67
84403		<1%	69	$946.67
86140		<1%	343	$931.31
84100		<1%	313	$907.77
80361		<1%	55	$844.19
83992		<1%	194	$814.86
80348		<1%	98	$748.78
80365		<1%	55	$748.78
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	543	$717.52
80354		<1%	55	$695.13
80356		<1%	82	$695.13
80373		<1%	54	$695.13
80349		<1%	80	$695.13
85652		<1%	400	$635.07
80358		<1%	54	$628.14
82550		<1%	173	$621.19
80353		<1%	82	$582.90
80360		<1%	52	$526.93
80366		<1%	36	$526.93
80368		<1%	53	$526.93
80355		<1%	53	$510.11
82043		<1%	555	$503.32
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	179	$475.15
84075		<1%	357	$464.75
84466		<1%	70	$445.17
80345		<1%	53	$440.51
80076		<1%	228	$410.12
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	16	$398.18
82172		<1%	13	$349.20
85611		<1%	159	$321.37
85610		<1%	143	$298.98
84550		<1%	201	$296.58
80202		<1%	40	$260.38
82565		<1%	178	$235.45
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,003	$228.52
84481		<1%	82	$196.42
84436		<1%	217	$156.86
82977		<1%	40	$145.10
84702		<1%	14	$137.17
83625		<1%	13	$127.08
84520		<1%	143	$124.64
86780		<1%	389	$120.01
86141		<1%	78	$118.03
86803		<1%	13	$116.81
84311		<1%	50	$115.00
82248		<1%	31	$87.36
82570		<1%	242	$82.02
86038		<1%	12	$80.42
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	12	$79.52
81001		<1%	43	$79.24
84154		<1%	12	$60.92
83986		<1%	50	$50.73
85730		<1%	13	$39.84
82947		<1%	102	$39.12
82247		0%	88	$0.00
80074		0%	281	$0.00
87501		0%	82	$0.00
80338		0%	15	$0.00
84295		0%	91	$0.00
80346		0%	32	$0.00
80375		0%	16	$0.00
80372		0%	19	$0.00
84155		0%	89	$0.00
82310		0%	89	$0.00
82465		0%	85	$0.00
82374		0%	88	$0.00
80364		0%	15	$0.00
82435		0%	89	$0.00
87070		0%	96	$0.00
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	0%	271	$0.00
82040		0%	88	$0.00
80329		0%	16	$0.00
84478		0%	86	$0.00
84132		0%	90	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialAHMAD, SAMI (PRESIDENT)